Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Saved in:
Bibliographic Details
Title: Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
Authors: Kito Y; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan. Electronic address: kitoyo9100@gmail.com., Yamazaki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yamada T; Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsushima T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Mitani S; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan., Shiraishi K; Department of Medical Oncology, Nagoya Medical Center, Aichi, Japan., Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan., Hara H; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Hirata K; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Shinohara Y; Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan., Tsuzuki T; Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan., Kajiura S; Third Department of Internal Medicine, University of Toyama, Toyama, Japan., Masuishi T; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan., Izawa N; Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan., Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Murata K; Department of Gastroenterological Surgery, Kansai Rosai Hospital, Hyogo, Japan., Akazawa N; Department of Gastrointestinal Surgery, Sendai City Medical Center, Sendai Open Hospital, Miyagi, Japan., Suzuki Y; Department of Gastroenterological Surgery, Toyonaka Municipal Hospital, Osaka, Japan., Satake H; Department of Medical Oncology, Kochi Medical School, Kochi, Japan., Boku N; Department of Oncology and General Medicine, IMSTU Hospital, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan., Hyodo I; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan., Yoshimura K; Graduate School of Medical Science, Nagoya City University, Aichi, Japan., Kawakami H; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Miyagi, Japan., Hironaka S; Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 May 02; Vol. 238, pp. 116688. Date of Electronic Publication: 2026 Mar 19.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2026.116688